This is a pilot study to describe the immunological responses and clinical outcome associated
with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor
(GM-CSF) as surgical adjuvant therapy in patients with malignant melanoma who are at high
risk for recurrence (Stage II T4, III and IV).